<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 18 Apr 2024 10:10:36 +0000</lastbuilddate>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>A Leadership Program to Support Career Development of Cardiovascular Chief Fellows</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38631779/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 23;83(16):1623-1625. doi: 10.1016/j.jacc.2024.02.030.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38631779/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38631779</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.030>10.1016/j.jacc.2024.02.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38631779</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Emily K Zern</dc:creator>
<dc:creator>Tripti Gupta</dc:creator>
<dc:creator>Hyeon-Ju Ryoo Ali</dc:creator>
<dc:creator>Prashanth Thakker</dc:creator>
<dc:creator>Nosheen Reza</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Leadership Program to Support Career Development of Cardiovascular Chief Fellows</dc:title>
<dc:identifier>pmid:38631779</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.030</dc:identifier>
</item>
<item>
<title>RESPONSE: Dispatches From a Neighboring Land</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38631778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 23;83(16):1622. doi: 10.1016/j.jacc.2024.01.038. Epub 2024 Mar 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38631778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38631778</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.038>10.1016/j.jacc.2024.01.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38631778</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Karen P Alexander</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>RESPONSE: Dispatches From a Neighboring Land</dc:title>
<dc:identifier>pmid:38631778</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.038</dc:identifier>
</item>
<item>
<title>Reflections on the Practice of Geriatric Cardiology After a Mid-Career Geriatrics Fellowship</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38631777/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 23;83(16):1619-1622. doi: 10.1016/j.jacc.2024.01.035.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38631777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38631777</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.035>10.1016/j.jacc.2024.01.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38631777</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Ashok Krishnaswami</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reflections on the Practice of Geriatric Cardiology After a Mid-Career Geriatrics Fellowship</dc:title>
<dc:identifier>pmid:38631777</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.035</dc:identifier>
</item>
<item>
<title>Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38631776/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to reduce adverse cardiovascular events in patients with type 2 diabetes mellitus, all-cause mortality, and heart failure hospitalization in patients with heart failure, as well as adverse renal outcomes. However, concerns regarding the heightened risk of genitourinary (GU) infections, particularly urinary tract infections, remain a significant barrier to their wider adoption. Addressing these misconceptions using existing...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 23;83(16):1568-1578. doi: 10.1016/j.jacc.2024.01.040.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to reduce adverse cardiovascular events in patients with type 2 diabetes mellitus, all-cause mortality, and heart failure hospitalization in patients with heart failure, as well as adverse renal outcomes. However, concerns regarding the heightened risk of genitourinary (GU) infections, particularly urinary tract infections, remain a significant barrier to their wider adoption. Addressing these misconceptions using existing evidence is needed to ensure proper risk-benefit assessment and optimal utilization of this efficacious therapy. This review aims to provide a balanced perspective on the evidence-based cardiovascular and renal benefits of SGLT2is and the associated risk of GU infections. We also summarize and propose clinical practice considerations for SGLT2i-associated GU infections focusing on patients with cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38631776/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38631776</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.040>10.1016/j.jacc.2024.01.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38631776</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Veraprapas Kittipibul</dc:creator>
<dc:creator>Zachary L Cox</dc:creator>
<dc:creator>Supavit Chesdachai</dc:creator>
<dc:creator>Mona Fiuzat</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:38631776</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.040</dc:identifier>
</item>
<item>
<title>Measurement and Application of Incidentally Detected Coronary Calcium: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38631775/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>Coronary artery calcium (CAC) scoring is a powerful tool for atherosclerotic cardiovascular disease risk stratification. The nongated, noncontrast chest computed tomography scan (NCCT) has emerged as a source of CAC characterization with tremendous potential due to the high volume of NCCT scans. Application of incidental CAC characterization from NCCT has raised questions around score accuracy, standardization of methodology including the possibility of deep learning to automate the process, and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 23;83(16):1557-1567. doi: 10.1016/j.jacc.2024.01.039.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Coronary artery calcium (CAC) scoring is a powerful tool for atherosclerotic cardiovascular disease risk stratification. The nongated, noncontrast chest computed tomography scan (NCCT) has emerged as a source of CAC characterization with tremendous potential due to the high volume of NCCT scans. Application of incidental CAC characterization from NCCT has raised questions around score accuracy, standardization of methodology including the possibility of deep learning to automate the process, and the risk stratification potential of an NCCT-derived score. In this review, the authors aim to summarize the role of NCCT-derived CAC in preventive cardiovascular health today as well as explore future avenues for eventual clinical applicability in specific patient populations and broader health systems.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38631775/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38631775</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.039>10.1016/j.jacc.2024.01.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38631775</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Shyon Parsa</dc:creator>
<dc:creator>Adam Saleh</dc:creator>
<dc:creator>Viraj Raygor</dc:creator>
<dc:creator>Natalie Hoeting</dc:creator>
<dc:creator>Anjali Rao</dc:creator>
<dc:creator>Ann Marie Navar</dc:creator>
<dc:creator>Anand Rohatgi</dc:creator>
<dc:creator>Fernando Kay</dc:creator>
<dc:creator>Suhny Abbara</dc:creator>
<dc:creator>Amit Khera</dc:creator>
<dc:creator>Parag H Joshi</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Measurement and Application of Incidentally Detected Coronary Calcium: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:38631775</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.039</dc:identifier>
</item>
<item>
<title>How Physical Activity Lowers Cardiovascular Risk: Exercise Can Change Your Mind</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38631774/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 23;83(16):1554-1556. doi: 10.1016/j.jacc.2024.03.369.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38631774/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38631774</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.369>10.1016/j.jacc.2024.03.369</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38631774</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Mitchell S V Elkind</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>How Physical Activity Lowers Cardiovascular Risk: Exercise Can Change Your Mind</dc:title>
<dc:identifier>pmid:38631774</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.369</dc:identifier>
</item>
<item>
<title>Effect of Stress-Related Neural Pathways on the Cardiovascular Benefit of Physical Activity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38631773/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: PA appears to reduce CVD risk in part by acting through the brain's stress-related activity; this may explain the novel observation that PA reduces CVD risk to a greater extent among individuals with depression.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 23;83(16):1543-1553. doi: 10.1016/j.jacc.2024.02.029.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The mechanisms underlying the psychological and cardiovascular disease (CVD) benefits of physical activity (PA) are not fully understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study tested whether PA: 1) attenuates stress-related neural activity, which is known to potentiate CVD and for its role in anxiety/depression; 2) decreases CVD in part through this neural effect; and 3) has a greater impact on CVD risk among individuals with depression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Participants from the Mass General Brigham Biobank who completed a PA survey were studied. A subset underwent <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomographic imaging. Stress-related neural activity was measured as the ratio of resting amygdalar-to-cortical activity (AmygA<sub>C</sub>). CVD events were ascertained from electronic health records.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 50,359 adults were included (median age 60 years [Q1-Q3: 45-70 years]; 40.1% male). Greater PA was associated with both lower AmygA<sub>C</sub> (standardized β: -0.245; 95% CI: -0.444 to -0.046; P = 0.016) and CVD events (HR: 0.802; 95% CI: 0.719-0.896; P &lt; 0.001) in multivariable models. AmygA<sub>C</sub> reductions partially mediated PA's CVD benefit (OR: 0.96; 95% CI: 0.92-0.99; P &lt; 0.05). Moreover, PA's benefit on incident CVD events was greater among those with (vs without) preexisting depression (HR: 0.860; 95% CI: 0.810-0.915; vs HR: 0.929; 95% CI: 0.910-0.949; P interaction = 0.011). Additionally, PA above guideline recommendations further reduced CVD events, but only among those with preexisting depression (P interaction = 0.023).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: PA appears to reduce CVD risk in part by acting through the brain's stress-related activity; this may explain the novel observation that PA reduces CVD risk to a greater extent among individuals with depression.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38631773/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38631773</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.029>10.1016/j.jacc.2024.02.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38631773</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Hadil Zureigat</dc:creator>
<dc:creator>Michael T Osborne</dc:creator>
<dc:creator>Shady Abohashem</dc:creator>
<dc:creator>Kenechukwu Mezue</dc:creator>
<dc:creator>Charbel Gharios</dc:creator>
<dc:creator>Simran Grewal</dc:creator>
<dc:creator>Alex Cardeiro</dc:creator>
<dc:creator>Nicki Naddaf</dc:creator>
<dc:creator>Giovanni Civieri</dc:creator>
<dc:creator>Taimur Abbasi</dc:creator>
<dc:creator>Azar Radfar</dc:creator>
<dc:creator>Wesam Aldosoky</dc:creator>
<dc:creator>Antonia V Seligowski</dc:creator>
<dc:creator>Meagan M Wasfy</dc:creator>
<dc:creator>James Sawalla Guseh</dc:creator>
<dc:creator>Timothy W Churchill</dc:creator>
<dc:creator>Rachel P Rosovsky</dc:creator>
<dc:creator>Zahi Fayad</dc:creator>
<dc:creator>Anthony Rosenzweig</dc:creator>
<dc:creator>Aaron Baggish</dc:creator>
<dc:creator>Roger K Pitman</dc:creator>
<dc:creator>Karmel W Choi</dc:creator>
<dc:creator>Jordan Smoller</dc:creator>
<dc:creator>Lisa M Shin</dc:creator>
<dc:creator>Ahmed Tawakol</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of Stress-Related Neural Pathways on the Cardiovascular Benefit of Physical Activity</dc:title>
<dc:identifier>pmid:38631773</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.029</dc:identifier>
</item>
<item>
<title>Lipoprotein(a): An Equal Opportunity Risk Factor</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38631772/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 23;83(16):1526-1528. doi: 10.1016/j.jacc.2024.03.356.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38631772/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38631772</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.356>10.1016/j.jacc.2024.03.356</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38631772</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregory G Schwartz</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lipoprotein(a): An Equal Opportunity Risk Factor</dc:title>
<dc:identifier>pmid:38631772</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.356</dc:identifier>
</item>
<item>
<title>Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38631771/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The study shows, in a large U.S. pooled cohort, that higher Lp(a) levels are associated with an increased ASCVD risk, including in patients with diabetes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 23;83(16):1511-1525. doi: 10.1016/j.jacc.2024.02.031.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Lipoprotein(a) (Lp[a]) is a causal genetic risk factor for atherosclerotic cardiovascular disease (ASCVD). There are limited long-term follow-up data from large U.S. population cohorts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study examined the relationship of Lp(a) with ASCVD outcomes in a large, pooled, multi-ethnic U.S.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The study included data on Lp(a) and ASCVD outcomes from 5 U.S.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">PROSPECTIVE STUDIES: MESA (Multi-Ethnic Study of Atherosclerosis), CARDIA (Coronary Artery Risk Development in Young Adults), JHS (Jackson Heart Study), FHS-OS (Framingham Heart Study-Offspring), and ARIC (Atherosclerosis Risk In Communities). Lp(a) levels were classified on the basis of cohort-specific percentiles. Multivariable Cox regression related Lp(a) with composite incident ASCVD events by risk group and diabetes status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study included 27,756 persons without previous ASCVD who were aged 20 to 79 years, including 55.0% women, 35.6% Black participants, and 7.6% patients with diabetes, with mean follow-up of 21.1 years. Compared with Lp(a) levels &lt;50th percentile, Lp(a) levels in the 50th to &lt;75th, 75th to &lt;90th, and ≥90th percentiles had adjusted HRs of 1.06 (95% CI: 0.99-1.14), 1.18 (95% CI: 1.09-1.28), and 1.46 (95% CI: 1.33-1.59), respectively for ASCVD events. Elevated Lp(a) predicted incident ASCVD events similarly by risk group, sex, and race or ethnic groups, but more strongly in patients with vs without diabetes (interaction P = 0.0056), with HRs for Lp(a) levels ≥90th percentile of 1.92 (95% CI: 1.50-2.45) and 1.41 (95% CI: 1.28-1.55), respectively. Lp(a) also individually predicted myocardial infarction, revascularization, stroke, and coronary heart disease death, but not total mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The study shows, in a large U.S. pooled cohort, that higher Lp(a) levels are associated with an increased ASCVD risk, including in patients with diabetes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38631771/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38631771</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.031>10.1016/j.jacc.2024.02.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38631771</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Nathan D Wong</dc:creator>
<dc:creator>Wenjun Fan</dc:creator>
<dc:creator>Xingdi Hu</dc:creator>
<dc:creator>Christie Ballantyne</dc:creator>
<dc:creator>Ron C Hoodgeveen</dc:creator>
<dc:creator>Michael Y Tsai</dc:creator>
<dc:creator>Auris Browne</dc:creator>
<dc:creator>Matthew J Budoff</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort</dc:title>
<dc:identifier>pmid:38631771</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.031</dc:identifier>
</item>
<item>
<title>The Course of Atrial Functional Mitral Regurgitation: The Atrium Dictates the Path</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38631770/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 23;83(16):1508-1510. doi: 10.1016/j.jacc.2024.03.357. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38631770/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38631770</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.357>10.1016/j.jacc.2024.03.357</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38631770</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Pieter M Vandervoort</dc:creator>
<dc:creator>Sébastien Deferm</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Course of Atrial Functional Mitral Regurgitation: The Atrium Dictates the Path</dc:title>
<dc:identifier>pmid:38631770</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.357</dc:identifier>
</item>
<item>
<title>Dual-role transcription factors stabilize intermediate expression levels</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38631355/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>Precise control of gene expression levels is essential for normal cell functions, yet how they are defined and tightly maintained, particularly at intermediate levels, remains elusive. Here, using a series of newly developed sequencing, imaging, and functional assays, we uncover a class of transcription factors with dual roles as activators and repressors, referred to as condensate-forming level-regulating dual-action transcription factors (TFs). They reduce high expression but increase low...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 10:S0092-8674(24)00314-3. doi: 10.1016/j.cell.2024.03.023. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Precise control of gene expression levels is essential for normal cell functions, yet how they are defined and tightly maintained, particularly at intermediate levels, remains elusive. Here, using a series of newly developed sequencing, imaging, and functional assays, we uncover a class of transcription factors with dual roles as activators and repressors, referred to as condensate-forming level-regulating dual-action transcription factors (TFs). They reduce high expression but increase low expression to achieve stable intermediate levels. Dual-action TFs directly exert activating and repressing functions via condensate-forming domains that compartmentalize core transcriptional unit selectively. Clinically relevant mutations in these domains, which are linked to a range of developmental disorders, impair condensate selectivity and dual-action TF activity. These results collectively address a fundamental question in expression regulation and demonstrate the potential of level-regulating dual-action TFs as powerful effectors for engineering controlled expression levels.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38631355/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38631355</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.023>10.1016/j.cell.2024.03.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38631355</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Jinnan He</dc:creator>
<dc:creator>Xiangru Huo</dc:creator>
<dc:creator>Gaofeng Pei</dc:creator>
<dc:creator>Zeran Jia</dc:creator>
<dc:creator>Yiming Yan</dc:creator>
<dc:creator>Jiawei Yu</dc:creator>
<dc:creator>Haozhi Qu</dc:creator>
<dc:creator>Yunxin Xie</dc:creator>
<dc:creator>Junsong Yuan</dc:creator>
<dc:creator>Yuan Zheng</dc:creator>
<dc:creator>Yanyan Hu</dc:creator>
<dc:creator>Minglei Shi</dc:creator>
<dc:creator>Kaiqiang You</dc:creator>
<dc:creator>Tingting Li</dc:creator>
<dc:creator>Tianhua Ma</dc:creator>
<dc:creator>Michael Q Zhang</dc:creator>
<dc:creator>Sheng Ding</dc:creator>
<dc:creator>Pilong Li</dc:creator>
<dc:creator>Yinqing Li</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Dual-role transcription factors stabilize intermediate expression levels</dc:title>
<dc:identifier>pmid:38631355</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.023</dc:identifier>
</item>
<item>
<title>The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38630857/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 17:ehad864. doi: 10.1093/eurheartj/ehad864. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38630857/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38630857</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad864>10.1093/eurheartj/ehad864</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38630857</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael A Borger</dc:creator>
<dc:creator>Victoria Delgado</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis</dc:title>
<dc:identifier>pmid:38630857</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad864</dc:identifier>
</item>
<item>
<title>Genetic testing in patients with unexplained coronary aneurysms or dilation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38630854/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 17:ehae217. doi: 10.1093/eurheartj/ehae217. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38630854/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38630854</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae217>10.1093/eurheartj/ehae217</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38630854</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>David Adlam</dc:creator>
<dc:creator>Fleur S van Dijk</dc:creator>
<dc:creator>Bart Loeys</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Genetic testing in patients with unexplained coronary aneurysms or dilation</dc:title>
<dc:identifier>pmid:38630854</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae217</dc:identifier>
</item>
<item>
<title>Correction to: XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38630622/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 17:ehae227. doi: 10.1093/eurheartj/ehae227. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38630622/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38630622</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae227>10.1093/eurheartj/ehae227</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38630622</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation</dc:title>
<dc:identifier>pmid:38630622</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae227</dc:identifier>
</item>
<item>
<title>Man in His Sixth Decade of Life With Totally Occluded Abdominal Aorta (Leriche Syndrome)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38630495/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Apr 17. doi: 10.1001/jamacardio.2024.0530. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38630495/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38630495</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0530>10.1001/jamacardio.2024.0530</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38630495</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Karley Fischer</dc:creator>
<dc:creator>Zuha Nazir</dc:creator>
<dc:creator>Damian Valencia</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Man in His Sixth Decade of Life With Totally Occluded Abdominal Aorta (Leriche Syndrome)</dc:title>
<dc:identifier>pmid:38630495</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0530</dc:identifier>
</item>
<item>
<title>Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38630494/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this post hoc analysis of the REDUCE LAP-HF II trial, over 2 years of follow-up, atrial shunting led to reverse remodeling of left-sided chambers and increases in volume of right-sided chambers consistent with the shunt flow but no change in RV systolic function compared with sham. Changes in cardiac structure/function were more favorable in responders compared with nonresponders treated with the shunt, supporting the previously identified responder group hypothesis...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Apr 17. doi: 10.1001/jamacardio.2024.0520. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Although the results of A Study to Evaluate the Corvia Medical Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients with Heart Failure (REDUCE LAP-HF II) trial were neutral overall, atrial shunt therapy demonstrated potential efficacy in responders (no latent pulmonary vascular disease and no cardiac rhythm management device). Post hoc analyses were conducted to evaluate the effect of shunt vs sham stratified by responder status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the effect of atrial shunt vs sham control on cardiac structure/function in the overall study and stratified by responder status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a sham-controlled randomized clinical trial of an atrial shunt device in heart failure with preserved ejection fraction (HFpEF)/HF with mildly reduced EF (HFmrEF). Trial participants with evaluable echocardiography scans were recruited from 89 international medical centers. Data were analyzed from April 2023 to January 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Atrial shunt device or sham control.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME MEASURES: Changes in echocardiographic measures from baseline to 1, 6, 12, and 24 months after index procedure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The modified intention-to-treat analysis of the REDUCE LAP-HF II trial included 621 randomized patients (median [IQR] age, 72.0 [66.0-77.0] years; 382 female [61.5%]; shunt arm, 309 [49.8%]; sham control arm, 312 [50.2%]). Through 24 months, 212 of 217 patients (98%) in the shunt arm with evaluable echocardiograms had patent shunts. In the overall trial population, the shunt reduced left ventricular (LV) end-diastolic volume (mean difference, -5.65 mL; P &lt;.001), left atrial (LA) minimal volume (mean difference, -2.8 mL; P =.01), and improved LV systolic tissue Doppler velocity (mean difference, 0.69 cm/s; P &lt;.001) and LA emptying fraction (mean difference, 1.88 percentage units; P =.02) compared with sham. Shunt treatment also increased right ventricular (RV; mean difference, 9.58 mL; P &lt;.001) and right atrial (RA; mean difference, 9.71 mL; P &lt;.001) volumes but had no effect on RV systolic function, pulmonary artery pressure, or RA pressure compared with sham. In the shunt arm, responders had smaller increases in RV end-diastolic volume (mean difference, 5.71 mL vs 15.18 mL; interaction P =.01), RV end-systolic volume (mean difference, 1.58 mL vs 7.89 mL; interaction P =.002), and RV/LV ratio (mean difference, 0.07 vs 0.20; interaction P &lt;.001) and larger increases in transmitral A wave velocity (mean difference, 5.08 cm/s vs -1.97 cm/s; interaction P =.02) compared with nonresponders randomized to the shunt, suggesting greater ability to accommodate shunted blood through the pulmonary circulation enabling LA unloading.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this post hoc analysis of the REDUCE LAP-HF II trial, over 2 years of follow-up, atrial shunting led to reverse remodeling of left-sided chambers and increases in volume of right-sided chambers consistent with the shunt flow but no change in RV systolic function compared with sham. Changes in cardiac structure/function were more favorable in responders compared with nonresponders treated with the shunt, supporting the previously identified responder group hypothesis and mechanism, although further evaluation with longer follow-up is needed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03088033.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38630494/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38630494</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0520>10.1001/jamacardio.2024.0520</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38630494</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Ravi B Patel</dc:creator>
<dc:creator>Frank E Silvestry</dc:creator>
<dc:creator>Jan Komtebedde</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Gerd Hasenfuß</dc:creator>
<dc:creator>Sheldon E Litwin</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Matthew J Price</dc:creator>
<dc:creator>Rami Kawash</dc:creator>
<dc:creator>Scott L Hummel</dc:creator>
<dc:creator>Donald E Cutlip</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Dirk J van Veldhuisen</dc:creator>
<dc:creator>Andreas J Rieth</dc:creator>
<dc:creator>Scott McKenzie</dc:creator>
<dc:creator>Heiko Bugger</dc:creator>
<dc:creator>Jeremy A Mazurek</dc:creator>
<dc:creator>Samir R Kapadia</dc:creator>
<dc:creator>Marc Vanderheyden</dc:creator>
<dc:creator>Bonnie Ky</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38630494</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0520</dc:identifier>
</item>
<item>
<title>Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38630489/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Among birisk patients with ACS who completed 9 to 12 months of DAPT after drug-eluting stent implantation and were free from adverse events for at least 6 months before randomization, an extended 9-month clopidogrel monotherapy regimen was superior to continuing DAPT with clopidogrel in reducing clinically relevant bleeding without increasing ischemic events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Apr 17. doi: 10.1001/jamacardio.2024.0534. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Purinergic receptor P2Y12 (P2Y12) inhibitor monotherapy after a certain period of dual antiplatelet therapy (DAPT) may be an attractive option of maintenance antiplatelet treatment for patients undergoing percutaneous coronary intervention (PCI) who are at both high bleeding and ischemic risk (birisk).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing DAPT with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in birisk patients with acute coronary syndromes (ACS).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, double-blind, placebo-controlled, randomized clinical trial including birisk patients with ACS who had completed 9 to 12 months of DAPT after drug-eluting stent implantation and were free from adverse events for at least 6 months at 101 China centers between February 2018 and December 2020. Study data were analyzed from April 2023 to May 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were randomized either to clopidogrel plus placebo or clopidogrel plus aspirin for an additional 9 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was Bleeding Academic Research Consortium (BARC) types 2, 3, or 5 bleeding 9 months after randomization. The key secondary end point was major adverse cardiac and cerebral events (MACCE; the composite of all-cause death, myocardial infarction, stroke or clinically driven revascularization). The primary end point was tested for superiority, and the MACCE end point was tested for sequential noninferiority and superiority.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 7758 patients (mean [SD] age, 64.8 [9.0] years; 4575 male [59.0%]) were included in this study. The primary end point of BARC types 2, 3, or 5 bleeding occurred in 95 of 3873 patients (2.5%) assigned to clopidogrel plus placebo and 127 of 3885 patients (3.3%) assigned to clopidogrel plus aspirin (hazard ratio [HR], 0.75; 95% CI, 0.57-0.97; difference, -0.8%; 95% CI, -1.6% to -0.1%; P = .03). The incidence of MACCE was 2.6% (101 of 3873 patients) in the clopidogrel plus placebo group and 3.5% (136 of 3885 patients) in the clopidogrel plus aspirin group (HR, 0.74; 95% CI, 0.57-0.96; difference, -0.9%; 95% CI, -1.7% to -0.1%; P &lt; .001 for noninferiority; P = .02 for superiority).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among birisk patients with ACS who completed 9 to 12 months of DAPT after drug-eluting stent implantation and were free from adverse events for at least 6 months before randomization, an extended 9-month clopidogrel monotherapy regimen was superior to continuing DAPT with clopidogrel in reducing clinically relevant bleeding without increasing ischemic events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03431142.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38630489/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38630489</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0534>10.1001/jamacardio.2024.0534</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38630489</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Yi Li</dc:creator>
<dc:creator>Jing Li</dc:creator>
<dc:creator>Bin Wang</dc:creator>
<dc:creator>Quanmin Jing</dc:creator>
<dc:creator>Yujie Zeng</dc:creator>
<dc:creator>Aijie Hou</dc:creator>
<dc:creator>Zhifang Wang</dc:creator>
<dc:creator>Aijun Liu</dc:creator>
<dc:creator>Jinliang Zhang</dc:creator>
<dc:creator>Yaojun Zhang</dc:creator>
<dc:creator>Ping Zhang</dc:creator>
<dc:creator>Daming Jiang</dc:creator>
<dc:creator>Bin Liu</dc:creator>
<dc:creator>Jiamao Fan</dc:creator>
<dc:creator>Jun Zhang</dc:creator>
<dc:creator>Li Li</dc:creator>
<dc:creator>Guohai Su</dc:creator>
<dc:creator>Ming Yang</dc:creator>
<dc:creator>Weihong Jiang</dc:creator>
<dc:creator>Peng Qu</dc:creator>
<dc:creator>Hesong Zeng</dc:creator>
<dc:creator>Lu Li</dc:creator>
<dc:creator>Miaohan Qiu</dc:creator>
<dc:creator>Leisheng Ru</dc:creator>
<dc:creator>Shaoliang Chen</dc:creator>
<dc:creator>Yujie Zhou</dc:creator>
<dc:creator>Shubin Qiao</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Yaling Han</dc:creator>
<dc:creator>OPT-BIRISK Investigators</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38630489</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0534</dc:identifier>
</item>
<item>
<title>Clopidogrel Monotherapy for Double-Risk Acute Coronary Syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38630487/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Apr 17. doi: 10.1001/jamacardio.2024.0547. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38630487/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38630487</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0547>10.1001/jamacardio.2024.0547</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38630487</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>Antonio Landi</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Clopidogrel Monotherapy for Double-Risk Acute Coronary Syndrome</dc:title>
<dc:identifier>pmid:38630487</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0547</dc:identifier>
</item>
<item>
<title>Orphan Nuclear Receptor NR4A3 Promotes Vascular Calcification via Histone Lactylation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38629274/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Taken together, our findings reveal that NR4A3-mediated histone lactylation is a novel metabolome-epigenome signaling cascade mechanism that participates in the pathogenesis of medial arterial calcification.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 17. doi: 10.1161/CIRCRESAHA.123.323699. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Medial arterial calcification is a chronic systemic vascular disorder distinct from atherosclerosis and is commonly observed in patients with chronic kidney disease, diabetes, and aging individuals. We previously showed that NR4A3 (nuclear receptor subfamily 4 group A member 3), an orphan nuclear receptor, is a key regulator in apo (apolipoprotein) A-IV-induced atherosclerosis progression; however, its role in vascular calcification is poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We generated NR4A3<sup>-/-</sup> mice and 2 different types of medial arterial calcification models to investigate the biological roles of NR4A3 in vascular calcification. RNA-seq was performed to determine the transcriptional profile of NR4A3<sup>-/-</sup> vascular smooth muscle cells under β-glycerophosphate treatment. We integrated CUT&amp;Tag analysis and RNA-seq data to further investigate the gene regulatory mechanisms of NR4A3 in arterial calcification and target genes regulated by histone lactylation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: NR4A3 expression was upregulated in calcified aortic tissues from chronic kidney disease mice, 1,25(OH)<sub>2</sub>VitD<sub>3</sub> overload-induced mice, and human calcified aorta. NR4A3 deficiency preserved the vascular smooth muscle cell contractile phenotype, inhibited osteoblast differentiation-related gene expression, and reduced calcium deposition in the vasculature. Further, NR4A3 deficiency lowered the glycolytic rate and lactate production during the calcification process and decreased histone lactylation. Mechanistic studies further showed that NR4A3 enhanced glycolysis activity by directly binding to the promoter regions of the 2 glycolysis genes <i>ALDOA</i> and <i>PFKL</i> and driving their transcriptional initiation. Furthermore, histone lactylation promoted medial calcification both in vivo and in vitro. NR4A3 deficiency inhibited the transcription activation and expression of Phospho1 (phosphatase orphan 1). Consistently, pharmacological inhibition of Phospho1-attenuated calcium deposition in NR4A3-overexpressed vascular smooth muscle cells, whereas overexpression of Phospho1 reversed the anticalcific effect of NR4A3 deficiency in vascular smooth muscle cells.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Taken together, our findings reveal that NR4A3-mediated histone lactylation is a novel metabolome-epigenome signaling cascade mechanism that participates in the pathogenesis of medial arterial calcification.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38629274/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38629274</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323699>10.1161/CIRCRESAHA.123.323699</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38629274</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Wenqi Ma</dc:creator>
<dc:creator>Kangni Jia</dc:creator>
<dc:creator>Haomai Cheng</dc:creator>
<dc:creator>Hong Xu</dc:creator>
<dc:creator>Zhigang Li</dc:creator>
<dc:creator>Hang Zhang</dc:creator>
<dc:creator>Hongyang Xie</dc:creator>
<dc:creator>Lingfang Zhuang</dc:creator>
<dc:creator>Ziyang Wang</dc:creator>
<dc:creator>Yuke Cui</dc:creator>
<dc:creator>Hang Sun</dc:creator>
<dc:creator>Lei Yi</dc:creator>
<dc:creator>Zhiyong Chen</dc:creator>
<dc:creator>Shengzhong Duan</dc:creator>
<dc:creator>Motoaki Sano</dc:creator>
<dc:creator>Keiichi Fukuda</dc:creator>
<dc:creator>Lin Lu</dc:creator>
<dc:creator>Fei Gao</dc:creator>
<dc:creator>Ruiyan Zhang</dc:creator>
<dc:creator>Xiaoxiang Yan</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Orphan Nuclear Receptor NR4A3 Promotes Vascular Calcification via Histone Lactylation</dc:title>
<dc:identifier>pmid:38629274</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323699</dc:identifier>
</item>
<item>
<title>The year in cardiovascular medicine 2023: the top 10 papers in arrhythmias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38628042/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 17:ehae189. doi: 10.1093/eurheartj/ehae189. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38628042/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38628042</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae189>10.1093/eurheartj/ehae189</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38628042</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Harry J G M Crijns</dc:creator>
<dc:creator>Pier D Lambiase</dc:creator>
<dc:creator>Prashantan Sanders</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2023: the top 10 papers in arrhythmias</dc:title>
<dc:identifier>pmid:38628042</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae189</dc:identifier>
</item>
<item>
<title>Gut bacteria can break down cholesterol</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38627565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240418061033&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Apr 16. doi: 10.1038/s41569-024-01026-w. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38627565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240418061033&v=2.18.0.post9+e462414">38627565</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01026-w>10.1038/s41569-024-01026-w</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38627565</guid>
<pubDate>Tue, 16 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2024-04-16</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Gut bacteria can break down cholesterol</dc:title>
<dc:identifier>pmid:38627565</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01026-w</dc:identifier>
</item>





























</channel>
</rss>